Faruqi & Faruqi Investigates Claims Against Sarepta Therapeutics for Potential Investor Claims

Faruqi & Faruqi Investigates Sarepta Therapeutics



Faruqi & Faruqi, LLP, a well-established national securities law firm, has initiated an investigation concerning potential claims against Sarepta Therapeutics, Inc. (NASDAQ: SRPT). This investigation predominantly targets claims filed by investors who purchased or acquired Sarepta securities within the period from June 22, 2023, to June 24, 2025. The law firm notably encourages these affected investors to reach out directly to discuss potential legal options.

According to the firm, there is a looming deadline of August 25, 2025, for investors seeking to take on the role of lead plaintiff in a federal securities class action against Sarepta. This opportunity is critical for investors who wish to represent the interests of the class and possibly recover losses experienced due to Sarepta's actions or omissions.

The complaints allege that Sarepta and its executives may have violated federal securities laws by making misleading or false statements. Specifically, these legal claims indicate potential serious safety risks associated with Sarepta's treatment, ELEVIDYS. The allegations cite that the clinical trial regimes and protocols governing the use of ELEVIDYS may have inadequately identified severe side effects. Furthermore, the adverse effects from the treatment reportedly led to the halting of patient recruitment and dosing during clinical trials, increasing scrutiny from regulatory bodies and posing greater risks concerning the therapy’s current and future approvals.

On March 18, 2025, Sarepta reported a safety update detailing a patient's death following treatment with ELEVIDYS. Following this announcement, the company's stock price experienced a significant drop of $27.81 per share, which accounted for a downturn of 27.44%, closing at $73.54 on the same day. Subsequent disclosures indicated that authorities within the European Union had requested a meeting with an independent data monitoring committee to review the concerning death from March 18. This revelation prompted Sarepta to suspend recruitment and dosing in certain ELEVIDYS clinical studies, resulting in a further share price decline.

On June 15, 2025, Sarepta disclosed another unfortunate incident: a second patient had died from acute liver failure after receiving treatment with ELEVIDYS. The company announced a temporary suspension of shipments for non-ambulatory patients while it evaluated trial regimens and collaborated with regulatory bodies. As anticipated, this news led to a dramatic decline in Sarepta's stock price, which plummeted by $15.24 per share, marking a 42.12% fall to $20.91 per share. The downturn indicated growing concerns about the company's ability to safely manage its clinical trials and maintain investor trust.

In a communication from June 24, 2025, the United States Food and Drug Administration (FDA) issued a Safety Communication about the ongoing investigations into the risks associated with ELEVIDYS. The FDA reported multiple deaths linked to the treatment along with serious adverse outcomes, emphasizing a need for regulatory action. Following this communication, Sarepta's stock saw an additional decline of $1.52 per share, ultimately closing at $17.46 on June 25.

Faruqi & Faruqi encourages all investors who might have relevant information regarding Sarepta's conduct to come forward. This outreach effort includes those who may have served as whistleblowers, former employees, or shareholders. For more details about the Sarepta Therapeutics class action, interested parties are invited to visit the firm’s website or contact partner Josh Wilson directly.

The full implications of the current investigation remain to be seen as the firm probes further into Sarepta's practices. Investor protection and transparency continue to be focal points in analyzing the recent events surrounding Sarepta Therapeutics and its product offerings. Keeping abreast of developments in this situation is crucial for stakeholders as the investigation progresses.

Topics Financial Services & Investing)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.